Published in Hepatology on February 01, 2009
Study of T Cell Phenotype Activation Pathway in Human Alcoholic Liver Disease | NCT00610597
Alcoholic liver disease: pathogenesis and new therapeutic targets. Gastroenterology (2011) 5.06
Interleukin-17 signaling in inflammatory, Kupffer cells, and hepatic stellate cells exacerbates liver fibrosis in mice. Gastroenterology (2012) 2.58
Interleukin-22 treatment ameliorates alcoholic liver injury in a murine model of chronic-binge ethanol feeding: role of signal transducer and activator of transcription 3. Hepatology (2010) 2.40
Osteopontin deficiency does not prevent but promotes alcoholic neutrophilic hepatitis in mice. Hepatology (2014) 2.17
CXCR3-dependent recruitment and CCR6-mediated positioning of Th-17 cells in the inflamed liver. J Hepatol (2012) 1.95
Deletion of interleukin (IL)-12p35 induces liver fibrosis in dominant-negative TGFβ receptor type II mice. Hepatology (2013) 1.78
Role of IL-17 and Th17 cells in liver diseases. Clin Dev Immunol (2010) 1.63
Innate immunity in alcoholic liver disease. Am J Physiol Gastrointest Liver Physiol (2011) 1.55
Alcoholic liver disease: pathogenesis and new targets for therapy. Nat Rev Gastroenterol Hepatol (2011) 1.52
Inflammation in alcoholic liver disease. Annu Rev Nutr (2012) 1.49
Alcohol, inflammation, and gut-liver-brain interactions in tissue damage and disease development. World J Gastroenterol (2010) 1.45
T Helper 17/Regulatory T Cell Balance and Experimental Models of Peritoneal Dialysis-Induced Damage. Biomed Res Int (2015) 1.41
Depletion of Foxp3+ Regulatory T Cells Promotes Profibrogenic Milieu of Cholestasis-Induced Liver Injury. Dig Dis Sci (2014) 1.40
Alcoholic liver disease: pathogenesis, management, and novel targets for therapy. J Gastroenterol Hepatol (2013) 1.35
Myeloid STAT3 inhibits T cell-mediated hepatitis by regulating T helper 1 cytokine and interleukin-17 production. Gastroenterology (2009) 1.34
Interleukin-17 contributes to the pathogenesis of autoimmune hepatitis through inducing hepatic interleukin-6 expression. PLoS One (2011) 1.27
Implication of Th17 and Th1 cells in patients with chronic active hepatitis B. J Clin Immunol (2009) 1.26
Th17 cells and their associated cytokines in liver diseases. Cell Mol Immunol (2010) 1.25
Interleukin-17 exacerbates hepatic steatosis and inflammation in non-alcoholic fatty liver disease. Clin Exp Immunol (2011) 1.25
High expression of IL-17 and IL-17RE associate with poor prognosis of hepatocellular carcinoma. J Exp Clin Cancer Res (2013) 1.24
The effect of inflammatory cytokines in alcoholic liver disease. Mediators Inflamm (2013) 1.18
Decreased ratio of Treg cells to Th17 cells correlates with HBV DNA suppression in chronic hepatitis B patients undergoing entecavir treatment. PLoS One (2010) 1.17
Innate immune cells in liver inflammation. Mediators Inflamm (2012) 1.11
Hyper-activated pro-inflammatory CD16 monocytes correlate with the severity of liver injury and fibrosis in patients with chronic hepatitis B. PLoS One (2011) 1.09
Inflammation-associated interleukin-6/signal transducer and activator of transcription 3 activation ameliorates alcoholic and nonalcoholic fatty liver diseases in interleukin-10-deficient mice. Hepatology (2011) 1.07
Pathogenesis of alcoholic liver disease: role of oxidative metabolism. World J Gastroenterol (2014) 1.06
Involvement of Th17 and Th1 effector responses in patients with Hepatitis B. J Clin Immunol (2010) 1.05
Autophagy: a multifaceted partner in liver fibrosis. Biomed Res Int (2014) 1.05
The role of chemokines in the recruitment of lymphocytes to the liver. Dig Dis (2010) 1.04
Interleukin (IL)-17/IL-22-producing T cells enriched within the liver of patients with chronic hepatitis C viral (HCV) infection. Dig Dis Sci (2011) 1.02
HCV+ hepatocytes induce human regulatory CD4+ T cells through the production of TGF-beta. PLoS One (2010) 1.01
Current understanding of osteoporosis associated with liver disease. Nat Rev Gastroenterol Hepatol (2009) 1.00
Evolving concepts in the pathogenesis of NASH: beyond steatosis and inflammation. Int J Mol Sci (2014) 1.00
Hepatitis C virus promotes T-helper (Th)17 responses through thymic stromal lymphopoietin production by infected hepatocytes. Hepatology (2013) 0.95
Molecular mechanism and treatment of viral hepatitis-related liver fibrosis. Int J Mol Sci (2014) 0.95
Hepatic expression of CCL2 in alcoholic liver disease is associated with disease severity and neutrophil infiltrates. Clin Exp Immunol (2012) 0.94
Genome-wide comparison between IL-17 and combined TNF-alpha/IL-17 induced genes in primary murine hepatocytes. BMC Genomics (2010) 0.92
Activated IL-23/IL-17 pathway closely correlates with increased Foxp3 expression in livers of chronic hepatitis B patients. BMC Immunol (2011) 0.92
Immune mechanisms in alcoholic liver disease. Genes Nutr (2009) 0.91
Osteoporosis and fractures in liver disease: relevance, pathogenesis and therapeutic implications. World J Gastroenterol (2014) 0.90
The pro-inflammatory effects of miR-155 promote liver fibrosis and alcohol-induced steatohepatitis. J Hepatol (2016) 0.90
Bone marrow-derived stem cells ameliorate hepatic fibrosis by down-regulating interleukin-17. Cell Biosci (2013) 0.90
Dynamic changes of clinical features that predict the prognosis of acute-on-chronic hepatitis B liver failure: a retrospective cohort study. Int J Med Sci (2013) 0.89
Characterization of HCV-specific CD4+Th17 immunity in recurrent hepatitis C-induced liver allograft fibrosis. Am J Transplant (2011) 0.89
Effects of N-acetylcysteine on cytokines in non-acetaminophen acute liver failure: potential mechanism of improvement in transplant-free survival. Liver Int (2013) 0.89
The potential of cytokines as safety biomarkers for drug-induced liver injury. Eur J Clin Pharmacol (2010) 0.89
Cellular and molecular functions of hepatic stellate cells in inflammatory responses and liver immunology. Hepatobiliary Surg Nutr (2014) 0.88
Inflammatory status in human hepatic cirrhosis. World J Gastroenterol (2015) 0.86
IL-17A synergistically enhances bile acid-induced inflammation during obstructive cholestasis. Am J Pathol (2013) 0.86
Protective role of interleukin-17 in murine NKT cell-driven acute experimental hepatitis. Am J Pathol (2010) 0.85
Clinical significance and gene expression study of human hepatic stellate cells in HBV related-hepatocellular carcinoma. J Exp Clin Cancer Res (2013) 0.84
Donor graft steatosis influences immunity to hepatitis C virus and allograft outcome after liver transplantation. Transplantation (2011) 0.84
Molecular mechanisms involved in the interaction effects of alcohol and hepatitis C virus in liver cirrhosis. Mol Med (2010) 0.83
Chronic liver inflammation: clinical implications beyond alcoholic liver disease. World J Gastroenterol (2014) 0.83
Interleukin-22 ameliorates liver fibrogenesis by attenuating hepatic stellate cell activation and downregulating the levels of inflammatory cytokines. World J Gastroenterol (2015) 0.83
Epidemiology and treatment of autoimmune hepatitis. Hepat Med (2012) 0.82
The peritoneal macrophage inflammatory profile in cirrhosis depends on the alcoholic or hepatitis C viral etiology and is related to ERK phosphorylation. BMC Immunol (2012) 0.82
Molecular targets in the treatment of alcoholic hepatitis. World J Gastroenterol (2012) 0.82
Role of microRNAs in Alcohol-Induced Multi-Organ Injury. Biomolecules (2015) 0.82
Differential modulation by IL-17A of Cholangitis versus Colitis in IL-2Rα deleted mice. PLoS One (2014) 0.82
Role of adaptive immunity in alcoholic liver disease. Int J Hepatol (2011) 0.81
Prognostic Significance of the Systemic Inflammatory and Immune Balance in Alcoholic Liver Disease with a Focus on Gender-Related Differences. PLoS One (2015) 0.80
IL-17A enhances the expression of profibrotic genes through upregulation of the TGF-β receptor on hepatic stellate cells in a JNK-dependent manner. J Immunol (2014) 0.80
Regulation of Inflammation by IL-17A and IL-17F Modulates Non-Alcoholic Fatty Liver Disease Pathogenesis. PLoS One (2016) 0.80
The role of innate cells is coupled to a Th1-polarized immune response in pediatric nonalcoholic steatohepatitis. J Clin Immunol (2012) 0.80
HMGB1/RAGE induces IL-17 expression to exaggerate inflammation in peripheral blood cells of hepatitis B patients. J Transl Med (2015) 0.79
T helper 17 cells in autoimmune liver diseases. Clin Dev Immunol (2013) 0.79
IL-17 Expression in the Time Course of Acute Anti-Thy1 Glomerulonephritis. PLoS One (2016) 0.79
IL-17 Axis Driven Inflammation in Non-Alcoholic Fatty Liver Disease Progression. Curr Drug Targets (2015) 0.78
Immune dysfunction in acute alcoholic hepatitis. World J Gastroenterol (2015) 0.78
Preservation of hepatic blood flow by direct peritoneal resuscitation improves survival and prevents hepatic inflammation following hemorrhagic shock. Am J Physiol Gastrointest Liver Physiol (2012) 0.78
Pathological role of interleukin-17 in poly I:C-induced hepatitis. PLoS One (2013) 0.78
Baicalin Attenuates IL-17-Mediated Acetaminophen-Induced Liver Injury in a Mouse Model. PLoS One (2016) 0.78
The Role of Innate Immunity in Alcoholic Liver Disease. Alcohol Res (2015) 0.78
Interleukin-17-targeted treatment of alcoholic liver disease. Hepatology (2009) 0.77
Liver inflammation and fibrosis. J Clin Invest (2017) 0.77
Highest frequencies of interleukin-22-producing T helper cells in alcoholic hepatitis patients with a favourable short-term course. PLoS One (2013) 0.77
Lentiviral vector-mediated down-regulation of IL-17A receptor in hepatic stellate cells results in decreased secretion of IL-6. World J Gastroenterol (2012) 0.77
Altered Gut Microbiota Composition and Immune Response in Experimental Steatohepatitis Mouse Models. Dig Dis Sci (2016) 0.76
New Approaches for Studying Alcoholic Liver Disease. Curr Pathobiol Rep (2014) 0.76
Antagonism of Interleukin-17A ameliorates experimental hepatic fibrosis by restoring the IL-10/STAT3-suppressed autophagy in hepatocytes. Oncotarget (2017) 0.76
Pathogenesis and Management of Alcoholic Liver Disease. Dig Dis (2016) 0.76
Plasma levels of growth-related oncogene (CXCL1-3) associated with fibrosis and platelet counts in HCV-infected patients. Aliment Pharmacol Ther (2015) 0.76
Emerging concepts in alcoholic hepatitis. World J Hepatol (2017) 0.75
Anti-IL-17 antibody improves hepatic steatosis by suppressing interleukin-17-related fatty acid synthesis and metabolism. Clin Dev Immunol (2013) 0.75
Docosahexaenoic acid blocks progression of western diet-induced nonalcoholic steatohepatitis in obese Ldlr-/- mice. PLoS One (2017) 0.75
Deregulation of Regulatory T Cells in Acute-on-Chronic Liver Failure: A Rat Model. Mediators Inflamm (2017) 0.75
C57BL/6 and A/J Mice Have Different Inflammatory Response and Liver Lipid Profile in Experimental Alcoholic Liver Disease. Mediators Inflamm (2015) 0.75
Immunity and inflammatory signaling in alcoholic liver disease. Hepatol Int (2014) 0.75
Alcoholic, Nonalcoholic, and Toxicant-Associated Steatohepatitis: Mechanistic Similarities and Differences. Cell Mol Gastroenterol Hepatol (2015) 0.75
Pathophysiology and Management of Alcoholic Liver Disease: Update 2016. Gut Liver (2017) 0.75
New treatment options for alcoholic hepatitis. World J Gastroenterol (2016) 0.75
The role of IL-17 signaling in regulation of the liver-brain axis and intestinal permeability in Alcoholic Liver Disease. Curr Pathobiol Rep (2016) 0.75
Levels of hepatic Th17 cells and regulatory T cells upregulated by hepatic stellate cells in advanced HBV-related liver fibrosis. J Transl Med (2017) 0.75
Pathology of Alcoholic Liver Disease. J Clin Transl Hepatol (2014) 0.75
Thymic NF-κB-inducing kinase regulates CD4(+) T cell-elicited liver injury and fibrosis in mice. J Hepatol (2017) 0.75
Interleukin-17F expression is elevated in hepatitis C patients with fibrosis and hepatocellular carcinoma. Infect Agent Cancer (2017) 0.75
Targeting inflammation for the treatment of alcoholic liver disease. Pharmacol Ther (2017) 0.75
Early liver transplantation for severe alcoholic hepatitis. N Engl J Med (2011) 8.50
Capsule endoscopy versus colonoscopy for the detection of polyps and cancer. N Engl J Med (2009) 6.31
Acute-on-chronic liver failure is a distinct syndrome that develops in patients with acute decompensation of cirrhosis. Gastroenterology (2013) 5.88
ABT-450/r-ombitasvir and dasabuvir with or without ribavirin for HCV. N Engl J Med (2014) 4.90
Endoscopic treatment for Zenker's diverticulum: long-term results (with video). Gastrointest Endosc (2013) 4.30
Stromal myofibroblasts are drivers of invasive cancer growth. Int J Cancer (2008) 4.30
Association between the PNPLA3 (rs738409 C>G) variant and hepatocellular carcinoma: Evidence from a meta-analysis of individual participant data. Hepatology (2014) 3.30
Sofosbuvir and Velpatasvir for HCV Genotype 1, 2, 4, 5, and 6 Infection. N Engl J Med (2015) 3.16
Endoscopic drainage of pancreatic-fluid collections in 116 patients: a comparison of etiologies, drainage techniques, and outcomes. Gastrointest Endosc (2006) 2.79
Prophylaxis of post-ERCP pancreatitis: a practice survey. Gastrointest Endosc (2010) 2.57
Single-operator cholangioscopy in patients requiring evaluation of bile duct disease or therapy of biliary stones (with videos). Gastrointest Endosc (2011) 2.30
Efficacy of radiofrequency ablation combined with endoscopic resection for barrett's esophagus with early neoplasia. Clin Gastroenterol Hepatol (2009) 2.28
Pancreatic-fluid collections: a randomized controlled trial regarding stent removal after endoscopic transmural drainage. Gastrointest Endosc (2007) 2.17
Antireflux transoral incisionless fundoplication using EsophyX: 12-month results of a prospective multicenter study. World J Surg (2008) 2.06
A case series of symptomatic intraluminal duodenal duplication cysts: presentation, endoscopic therapy, and long-term outcome (with video). Gastrointest Endosc (2008) 2.06
Computed tomography and magnetic resonance imaging in the assessment of acute pancreatitis. Gastroenterology (2004) 2.02
EUS-guided pancreatogastrostomy and pancreatobulbostomy for the treatment of pain in patients with pancreatic ductal dilatation inaccessible for transpapillary endoscopic therapy. Gastrointest Endosc (2007) 2.01
Active delivery of trefoil factors by genetically modified Lactococcus lactis prevents and heals acute colitis in mice. Gastroenterology (2004) 1.99
The protease inhibitor, GS-9256, and non-nucleoside polymerase inhibitor tegobuvir alone, with ribavirin, or pegylated interferon plus ribavirin in hepatitis C. Hepatology (2012) 1.97
Prednisolone with vs without pentoxifylline and survival of patients with severe alcoholic hepatitis: a randomized clinical trial. JAMA (2013) 1.94
Predicted effects of treatment for HCV infection vary among European countries. Gastroenterology (2012) 1.89
Advanced glycation end products induce production of reactive oxygen species via the activation of NADPH oxidase in murine hepatic stellate cells. J Hepatol (2009) 1.89
CCR5 deficiency exacerbates T-cell-mediated hepatitis in mice. Hepatology (2005) 1.88
Endoscopic removal of dysfunctioning bands or rings after restrictive bariatric procedures. Gastrointest Endosc (2009) 1.84
Reversal of autoimmune diabetes by restoration of antigen-specific tolerance using genetically modified Lactococcus lactis in mice. J Clin Invest (2012) 1.84
Endoscopic implantation of enteryx for treatment of GERD: 12-month results of a prospective, multicenter trial. Am J Gastroenterol (2003) 1.84
Chronic administration of valproic acid inhibits activation of mouse hepatic stellate cells in vitro and in vivo. Hepatology (2010) 1.82
Efficacy of endoscopic closure of acute perforations of the gastrointestinal tract. Clin Gastroenterol Hepatol (2012) 1.77
Insulin resistance in hepatocytes and sinusoidal liver cells: mechanisms and consequences. J Hepatol (2007) 1.75
Endoscopic treatment of external pancreatic fistulas: when draining the main pancreatic duct is not enough. Am J Gastroenterol (2007) 1.74
Impact of insulin resistance on sustained response in HCV patients treated with pegylated interferon and ribavirin: a meta-analysis. J Hepatol (2011) 1.73
Self-expanding plastic stents for benign esophageal lesions. Gastrointest Endosc (2004) 1.72
Differential liver sensitization to toll-like receptor pathways in mice with alcoholic fatty liver. Hepatology (2006) 1.68
Clinical impact of biliary drainage and jaundice resolution in patients with obstructive metastases at the hilum. Am J Gastroenterol (2003) 1.67
Levels of gemcitabine transport and metabolism proteins predict survival times of patients treated with gemcitabine for pancreatic adenocarcinoma. Gastroenterology (2012) 1.67
Human equilibrative nucleoside transporter 1 and human concentrative nucleoside transporter 3 predict survival after adjuvant gemcitabine therapy in resected pancreatic adenocarcinoma. Clin Cancer Res (2009) 1.62
Enteryx implantation for GERD: expanded multicenter trial results and interim postapproval follow-up to 24 months. Gastrointest Endosc (2005) 1.62
Pancreatic tuberculosis diagnosed by EUS: one disease, many faces. JOP (2013) 1.62
Role of a cirrhosis risk score for the early prediction of fibrosis progression in hepatitis C patients with minimal liver disease. J Hepatol (2010) 1.57
Hetero-oligomerization of CCR2, CCR5, and CXCR4 and the protean effects of "selective" antagonists. J Biol Chem (2009) 1.55
Management of bacterial infections in cirrhosis. J Hepatol (2012) 1.54
EUS-guided pancreaticogastrostomy. Gastrointest Endosc (2002) 1.50
Endoscopic cystenterostomy of nonbulging pancreatic fluid collections. Gastrointest Endosc (2002) 1.50
Impact of patatin-like phospholipase-3 (rs738409 C>G) polymorphism on fibrosis progression and steatosis in chronic hepatitis C. Hepatology (2011) 1.49
A dramatic case of calciphylaxis 20 years after kidney transplantation. Nephrol Dial Transplant (2004) 1.47
Reduced medication dependency and improved symptoms and quality of life 12 months after enteryx implantation for gastroesophageal reflux. J Clin Gastroenterol (2005) 1.46
Mouse ChemR23 is expressed in dendritic cell subsets and macrophages, and mediates an anti-inflammatory activity of chemerin in a lung disease model. J Immunol (2009) 1.45
Aminopyrine breath test compared to the MELD and Child-Pugh scores for predicting mortality among cirrhotic patients awaiting liver transplantation. Transpl Int (2003) 1.44
Self-expandable metal stents for the treatment of benign upper GI leaks and perforations. Gastrointest Endosc (2011) 1.42
Microsatellite polymorphism in the heme oxygenase-1 gene promoter is not associated with alcoholic liver disease severity. Hepatology (2013) 1.39
Trichostatin A, a histone deacetylase inhibitor, suppresses collagen synthesis and prevents TGF-beta(1)-induced fibrogenesis in skin fibroblasts. Exp Cell Res (2002) 1.36
Macrophages expressing the scavenger receptor CD163: a link between immune alterations of the gut and synovial inflammation in spondyloarthropathy. J Pathol (2002) 1.34
High-density lipoproteins reduce the neutralizing effect of hepatitis C virus (HCV)-infected patient antibodies by promoting HCV entry. J Gen Virol (2006) 1.31
Endoscopic implantation of a biopolymer in the lower esophageal sphincter for gastroesophageal reflux: a pilot study. Gastrointest Endosc (2002) 1.25
The histone-deacetylase inhibitor Trichostatin A blocks proliferation and triggers apoptotic programs in hepatoma cells. J Hepatol (2002) 1.25
Common polymorphism in the PNPLA3/adiponutrin gene confers higher risk of cirrhosis and liver damage in alcoholic liver disease. J Hepatol (2011) 1.23
Rapid viral response of once-daily TMC435 plus pegylated interferon/ribavirin in hepatitis C genotype-1 patients: a randomized trial. Antivir Ther (2011) 1.22
Virologic response and characterisation of HCV genotype 2-6 in patients receiving TMC435 monotherapy (study TMC435-C202). J Hepatol (2012) 1.22
EUS-guided cholecystenterostomy: a new technique (with videos). Gastrointest Endosc (2007) 1.21
Endogenous interleukin-10 modulates fibrosis and regeneration in experimental chronic pancreatitis. Am J Physiol Gastrointest Liver Physiol (2002) 1.20